.Pharmacolibrary.Drugs.ATC.N.N02BF03_1 .Pharmacolibrary.Drugs.ATC.N.N02BF03_1| name: | Mirogabalin_1 |
| ATC code: | N02BF03_1 | route: | oral |
| n-compartments | 2 |
Mirogabalin is an oral gabapentinoid derivative developed for the treatment of neuropathic pain, including diabetic peripheral neuropathic pain and postherpetic neuralgia. It is a selective ligand for the α2δ subunit of voltage-gated calcium channels. Mirogabalin is approved in Japan and several Asian countries for pain management.
Population PK analysis from pooled adult studies, median age 50, mixed sex, various doses (therapeutic range).
Yin, OQ, et al., & Miller, R (2016). Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin. Journal of clinical pharmacology 56(2) 203–212. DOI:10.1002/jcph.584 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26138993
Toyama, K, et al., & Ishizuka, H (2023). Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants. Clinical pharmacology in drug development 12(10) 985–990. DOI:10.1002/cpdd.1292 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37312273
Li, Y, et al., & Wu, X (2023). Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study. Advances in therapy 40(4) 1628–1643. DOI:10.1007/s12325-022-02424-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36790683